title: The effect of alendronate sodium on human erythrocytes.
abstract: Alendronate sodium is a medicine, which is commonly used in osteoporosis treatment. Nowadays, this substance is given to patients in tablets, but in future it is planned that it will be administrated into human organisms as intravenous infusions; therefore, significant interactions of this medicine with erythrocytes will be inevitable. It is the reason why we decided to investigate the interaction of alendronate sodium with human erythrocytes. The effect of this medicine on acetylcholinesterase activity, lipid and protein peroxidation, as well as cellular thiol content was examined. Moreover, the effect of alendronate sodium on alterations in erythrocytes morphology was assessed. Human erythrocytes were incubated with alendronate sodium in the concentrations ranging from 0.33 to 100 μM for 1 h and 24 h. No changes have been observed in the parameters examined after 1h of incubation of the erythrocytes with this medicine excluding the carbonyl groups level. Moreover, no alterations in the activity of acetylcholinesterase, the level of thiols as well as in morphology of the erythrocytes incubated with alendronate sodium for 24h have been observed. It was also proven that alendronate sodium increased the level of reactive oxygen species (ROS) but only after 24h of incubation. We have not observed any severe changes in cells studied even at the highest dose of bisphosphonates examined, thus their usage should not be dangerous for the erythrocytes of people treated with these medicines.
authors.affiliation: Department of Biophysics of Environmental Pollution, University of Łódź, Pomorska 141/143 Str., 90-237 Łódź, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Kopka
authors.forename: Sylwia
authors.initials: S
authors.lastname: Janiszewska
authors.forename: Marzena
authors.initials: M
authors.lastname: Szwed
authors.forename: Wirgiliusz
authors.initials: W
authors.lastname: Duda
authors.forename: Bożena
authors.initials: B
authors.lastname: Bukowska
mesh_terms: D000110:Acetylcholinesterase / Q000378:metabolism; D019386:Alendronate / Q000494:pharmacology*; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D004164:Diphosphonates / Q000494:pharmacology; D004912:Erythrocytes / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D005978:Glutathione / Q000378:metabolism; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D017382:Reactive Oxygen Species / Q000378:metabolism; D013438:Sulfhydryl Compounds / Q000378:metabolism
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D017382:Reactive Oxygen Species; D013438:Sulfhydryl Compounds; D000110:Acetylcholinesterase; D005978:Glutathione; D019386:Alendronate